Advertisement
Regeneron Pharma Expects Q4 Results To Include $24 Mln In Acquired In-process R&D Charge
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) said Monday it currently expects that its financial results for the second quarter 2024 will include an acquired in-process research and development charge of approximately $24 million on a pre-tax basis.
This charge relates to up-front payments, as well as a premium on equity securities purchased, in connection with collaboration and licensing agreements.
This charge is expected to negatively impact each of GAAP and non-GAAP net income per share for the second quarter 2024 by approximately $0.18.
read more
Regeneron Pharma Q2 Results Top Estimates - Update
Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) reported on Thursday that net income for the second quarter increased to $1.43 billion or $12.41 per share from $968 million or $8.50 per share in the prior-year quarter.
RTTNews
|
441 dias atrás
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU
Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
RTTNews
|
475 dias atrás
Regeneron Pharma Q4 Results Top Estimates - Update
Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.
RTTNews
|
622 dias atrás
Regeneron Completes Acquiring Sanofi's Stake In Libtayo
Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
RTTNews
|
1203 dias atrás
DAX Down Slightly; Sartorius Soars 10% On Strong Sales Forecast
German stocks are turning in a mixed performance on Thursday as investors largely stay cautious amid a lack of fresh data, and await earnings updates and continue to monitor political developments in France.
RTTNews
|
18 minutos atrás
Pound Rises Against Majors
The British pound strengthened against other major currencies in the European session on Thursday.
RTTNews
|
30 minutos atrás
NZ Dollar Rises Amid Ongoing Global Trade Tensions
The New Zealand dollar strengthened against other major currencies in the Asian session on Thursday. The U.S. Democrats and Republicans prepare for a prolonged government shutdown after the Senate failed to pass legislation restoring funding amid escalating U.S.-China trade tensions.
RTTNews
|
42 minutos atrás
Yen Falls Amid Political Uncertainty
The Japanese yen weakened against other major currencies in the Asian session on Thursday, with uncertainty surrounding the Liberal Democratic Party's leadership race following its coalition split with Komeito.
RTTNews
|
1h 39min atrás
